The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy

Human Reproduction

Volumn 17, Issue 9, 2002, Pages 2315-2319

  Honkanen, Helena ^a   Ranta, Sirpa ^b   Ylikorkala, Olavi ^a   Heikinheimo, Oskari ^a,b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

hCG; Medical abortion; Mifepristone; Misoprostol; Progesterone

Indexed keywords

CHORIONIC GONADOTROPIN; MIFEPRISTONE; MISOPROSTOL; PLACEBO; PROGESTERONE;

ADULT; AMENORRHEA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; DRUG METABOLISM; DRUG RESPONSE; ENDOCRINOLOGY; FEMALE; FIRST TRIMESTER PREGNANCY; GONADOTROPIN BLOOD LEVEL; HORMONE METABOLISM; HUMAN; LONG TERM CARE; MULTICENTER STUDY; PREGNANCY TERMINATION; PROGESTERONE BLOOD LEVEL; PROGESTERONE METABOLISM; RANDOMIZED CONTROLLED TRIAL; SERUM; STATISTICAL ANALYSIS; TREATMENT PLANNING; TROPHOBLAST;

EID: 0036713633     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/17.9.2315     Document Type: Article

References (19)

1. An effective regimen for early medical abortion: A report of 2000 consecutive cases
2. The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: A comparison of three dose regimens
3. Antifertility effects of the progesterone antagonist RU 486 include direct inhibition of placental hormone secretion
4. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol
5. Comparison between oral and vaginal administration of misoprostol on uterine contractility
6. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography
7. Pharmacokinetics of the antiprogesterone RU 486: No correlation to clinical performance of RU 486
8. Circulating levels of placental protein 14 and progesterone following mifepristone (RU 38486) and gemeprost for termination of first trimester pregnancy
9. The disappearance of hCG and return of pituitary function after abortion
10. Circulating levels of placental protein 12 and chorionic gonadotrophin following RU 38486 and gemeprost for termination of first trimester pregnancy
11. Functional evidence for divergent receptor activation mechanisms of luteotrophic and luteolytic events in the human corpus luteum
12. Reproductive hormones during termination of early pregnancy with mifepristone
13. Early pregnancy termination with mifepristone and misoprostol in the United States
14. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin
15. Pilot study on the use of a two-week course of oral misoprostol in patients after termination of pregnancy with mifepristone and misoprostol
16. Pharmacokinetics of different routes of administration of misoprostol
17. Monitoring serum chorionic gonadotrophin levels after mifepristone abortion
18. Termination of pregnancy with reduced doses of mifepristone
19. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: A randomised trial